Welcome to our dedicated page for Tharimmune news (Ticker: THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.
Tharimmune, Inc. (NASDAQ: THAR) generates news across two distinct but connected areas: clinical-stage biotechnology and digital asset treasury activities centered on Canton Coin and the Canton Network. Company press releases highlight progress for its lead asset TH104, an investigational nalmefene buccal film being advanced via a 505(b)(2) NDA pathway as a prophylactic countermeasure against respiratory and nervous system depression from high-potency opioids in military personnel and chemical incident responders.
News coverage frequently includes regulatory milestones such as positive feedback from the U.S. Food and Drug Administration (FDA) on Tharimmune’s pharmacokinetic modeling plan for TH104 and confirmation that no additional clinical trials appear necessary for a specified indication. Updates also address intellectual property developments, including patents granted or allowed in multiple countries for the TH104 transmucosal film technology, and corporate developments such as board appointments and leadership changes aligned with the company’s national security and addiction-related focus.
Tharimmune also issues news about its broader pipeline, including TH023, a novel oral monoclonal antibody program targeting TNF-alpha, and an early-stage multispecific biologic platform using its proprietary EpiClick™ Technology for solid tumors. These releases describe preclinical data, planned development steps, and strategic licensing arrangements.
On the digital asset side, Tharimmune’s news flow covers private placements, securities purchase agreements, and treasury strategy updates related to Canton Coin. The company reports on transactions led by institutional investors, its intention to operate as a Super Validator on the Canton Network, and commentary on initiatives such as the tokenization of U.S. Treasury securities on that network. Investors following THAR news can therefore expect a mix of clinical, regulatory, intellectual property, governance, financing, and blockchain-related announcements. Bookmarking this page provides a single stream of these updates as they are released.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.